My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

67.72 +1.67 (+2.53%)

Streaming Delayed Price Updated: 3:35 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

92 93 Next >

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

October 31, 2024

From Bristol Myers Squibb

Via Business Wire

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb ↗

October 23, 2024

Via Benzinga

Unveiling 11 Analyst Insights On Bristol-Myers Squibb ↗

October 07, 2024

Via Benzinga

Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

BMY earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit ↗

October 31, 2024

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates.

Via Benzinga

Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance ↗

October 31, 2024

The pharma giant has been trading tightly in recent weeks.

Via Investor's Business Daily

Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

October 31, 2024

From Bristol Myers Squibb

Via Business Wire

Markets Give Back Gains As Hovering Continues ↗

October 30, 2024

Market indexes could not hold onto earlier gains this afternoon, and all closed near session lows. The moves were mild, though — as we’ve stated in this space previously, the big news the market is...

Via Talk Markets

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024

October 28, 2024

From Bristol Myers Squibb

Via Business Wire

What Lies In Store For Healthcare ETFs In Q3 Earnings? ↗

October 27, 2024

The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.

Via Talk Markets

Topics ETFs

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗

October 23, 2024

EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes.

Via Benzinga

Why Is Evotec Stock Gaining Today? ↗

October 23, 2024

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

Via Benzinga

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗

October 17, 2024

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...

Via Benzinga

Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold? ↗

October 16, 2024

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

Via The Motley Fool

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗

October 15, 2024

The company could have a long path ahead to reimbursement and, ultimately, sales.

Via Investor's Business Daily

Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 ↗

October 12, 2024

Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock.

Via Talk Markets

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report ↗

October 11, 2024

Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals.

Via Benzinga

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst ↗

October 07, 2024

The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 07, 2024

Via Benzinga

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion' ↗

October 07, 2024

Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.

Via Benzinga

Topics Artificial Intelligence Stocks

Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound? ↗

October 07, 2024

Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround.

Via Benzinga

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting ↗

October 04, 2024

FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.

Via Benzinga

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

October 03, 2024

From Bristol Myers Squibb

Via Business Wire

2 Passive-Income Stocks to Load Up On in October ↗

October 03, 2024

These two dividend powerhouses are ideal choices for passive-income investors.

Via The Motley Fool

Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear ↗

October 03, 2024

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Via Investor's Business Daily

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.